Clinical effectiveness of trimetazidine as a leading cardiovascular drug with metabolic action
Trimetazidine is proved to be a highly effective metabolic agent, compared to other drugs with the same action. Trimetazidine shifts cardiac energy metabolism from fatty acid oxidation towards glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl-coenzyme A thiolase. In a number of ran...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«SILICEA-POLIGRAF» LLC
2008-08-01
|
| Series: | Кардиоваскулярная терапия и профилактика |
| Subjects: | |
| Online Access: | https://cardiovascular.elpub.ru/jour/article/view/1619 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850028133556682752 |
|---|---|
| author | A. Yu. Gasparyan A. H. Petrosyan L. M. Ayvazyan |
| author_facet | A. Yu. Gasparyan A. H. Petrosyan L. M. Ayvazyan |
| author_sort | A. Yu. Gasparyan |
| collection | DOAJ |
| description | Trimetazidine is proved to be a highly effective metabolic agent, compared to other drugs with the same action. Trimetazidine shifts cardiac energy metabolism from fatty acid oxidation towards glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl-coenzyme A thiolase. In a number of randomized controlled trials, trimetazidine was shown to improve the ergometric exercise capacity and total workload, to reduce angina attacks and nitroglycerin total dose in patients with coronary heart disease, heart failure, and after coronary artery bypass graft surgery. It is especially important that trimetazidine is highly effective in diabetes-associated cardiac pathology. Clinical effectiveness of other metabolic agents is also discussed, and directions for further research are presented, based on evidence-based data analysis. |
| format | Article |
| id | doaj-art-409d4204fcf448a7973731c8a987f41b |
| institution | DOAJ |
| issn | 1728-8800 2619-0125 |
| language | Russian |
| publishDate | 2008-08-01 |
| publisher | «SILICEA-POLIGRAF» LLC |
| record_format | Article |
| series | Кардиоваскулярная терапия и профилактика |
| spelling | doaj-art-409d4204fcf448a7973731c8a987f41b2025-08-20T02:59:56Zrus«SILICEA-POLIGRAF» LLCКардиоваскулярная терапия и профилактика1728-88002619-01252008-08-01741011061336Clinical effectiveness of trimetazidine as a leading cardiovascular drug with metabolic actionA. Yu. Gasparyan0A. H. Petrosyan1L. M. Ayvazyan2M. Heratsi Yerevan State Medical University. YerevanM. Heratsi Yerevan State Medical University. YerevanM. Heratsi Yerevan State Medical University. YerevanTrimetazidine is proved to be a highly effective metabolic agent, compared to other drugs with the same action. Trimetazidine shifts cardiac energy metabolism from fatty acid oxidation towards glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl-coenzyme A thiolase. In a number of randomized controlled trials, trimetazidine was shown to improve the ergometric exercise capacity and total workload, to reduce angina attacks and nitroglycerin total dose in patients with coronary heart disease, heart failure, and after coronary artery bypass graft surgery. It is especially important that trimetazidine is highly effective in diabetes-associated cardiac pathology. Clinical effectiveness of other metabolic agents is also discussed, and directions for further research are presented, based on evidence-based data analysis.https://cardiovascular.elpub.ru/jour/article/view/1619trimetazidine3-ketoacyl-coenzyme a thiolasecoronary artery diseaseheart failuretreatmenteffectiveness |
| spellingShingle | A. Yu. Gasparyan A. H. Petrosyan L. M. Ayvazyan Clinical effectiveness of trimetazidine as a leading cardiovascular drug with metabolic action Кардиоваскулярная терапия и профилактика trimetazidine 3-ketoacyl-coenzyme a thiolase coronary artery disease heart failure treatment effectiveness |
| title | Clinical effectiveness of trimetazidine as a leading cardiovascular drug with metabolic action |
| title_full | Clinical effectiveness of trimetazidine as a leading cardiovascular drug with metabolic action |
| title_fullStr | Clinical effectiveness of trimetazidine as a leading cardiovascular drug with metabolic action |
| title_full_unstemmed | Clinical effectiveness of trimetazidine as a leading cardiovascular drug with metabolic action |
| title_short | Clinical effectiveness of trimetazidine as a leading cardiovascular drug with metabolic action |
| title_sort | clinical effectiveness of trimetazidine as a leading cardiovascular drug with metabolic action |
| topic | trimetazidine 3-ketoacyl-coenzyme a thiolase coronary artery disease heart failure treatment effectiveness |
| url | https://cardiovascular.elpub.ru/jour/article/view/1619 |
| work_keys_str_mv | AT ayugasparyan clinicaleffectivenessoftrimetazidineasaleadingcardiovasculardrugwithmetabolicaction AT ahpetrosyan clinicaleffectivenessoftrimetazidineasaleadingcardiovasculardrugwithmetabolicaction AT lmayvazyan clinicaleffectivenessoftrimetazidineasaleadingcardiovasculardrugwithmetabolicaction |